| Literature DB >> 32915473 |
Maria Gil-Moles1, Uttara Basu1, Rolf Büssing1, Henrik Hoffmeister1, Sebastian Türck1, Agnieszka Varchmin1, Ingo Ott1.
Abstract
Gold complexes have a long tradition in medicine and for many examples antirheumatic, anticancer or anti-infective effects have been confirmed. Herein, we evaluated the lead compound Auranofin and five selected gold organometallics as inhibitors of two relevant drug targets of severe acute respiratory syndrome coronaviruses (SARS-CoV). The gold metallodrugs were effective inhibitors of the interaction of the SARS-CoV-2 spike protein with the angiotensin converting enzyme 2 (ACE2) host receptor and might thus interfere with the viral entry process. The gold metallodrugs were also efficient inhibitors of the papain-like protease (PLpro) of SARS-CoV-1 and SARS-CoV-2, which is a key enzyme in the viral replication. Regarding PLpro from SARS-CoV-2, the here reported inhibitors are among the very first experimentally confirmed examples with activity against this target enzyme. Importantly, the activity of the complexes against both PLpro enzymes correlated with the ability of the inhibitors to remove zinc ions from the labile zinc center of the enzyme. Taken together, the results of this pilot study suggest further evaluation of gold complexes as SARS-CoV antiviral drugs.Entities:
Keywords: Auranofin; SARS-CoV-2; coronavirus; gold complexes; metallodrugs
Mesh:
Substances:
Year: 2020 PMID: 32915473 PMCID: PMC7756435 DOI: 10.1002/chem.202004112
Source DB: PubMed Journal: Chemistry ISSN: 0947-6539 Impact factor: 5.236